Curative Biotechnology Stock Performance
| CUBT Stock | USD 0 0.0005 9.26% |
The firm shows a Beta (market volatility) of -0.79, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Curative Biotechnology are expected to decrease at a much lower rate. During the bear market, Curative Biotechnology is likely to outperform the market. Curative Biotechnology right now shows a risk of 13.01%. Please confirm Curative Biotechnology maximum drawdown, as well as the relationship between the expected short fall and day median price , to decide if Curative Biotechnology will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Curative Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively fragile fundamental drivers, Curative Biotechnology may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Curative Biotechnology Relative Risk vs. Return Landscape
If you would invest 0.83 in Curative Biotechnology on October 5, 2025 and sell it today you would lose (0.29) from holding Curative Biotechnology or give up 34.94% of portfolio value over 90 days. Curative Biotechnology is currently generating 0.1146% in daily expected returns and assumes 13.0123% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Curative, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Curative Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Curative Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Curative Biotechnology, and traders can use it to determine the average amount a Curative Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0088
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | CUBT |
| Negative Returns |
Based on monthly moving average Curative Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Curative Biotechnology by adding Curative Biotechnology to a well-diversified portfolio.
Curative Biotechnology Fundamentals Growth
Curative Stock prices reflect investors' perceptions of the future prospects and financial health of Curative Biotechnology, and Curative Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Curative Stock performance.
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.64 | ||||
| Current Valuation | 5.79 M | ||||
| Shares Outstanding | 1.05 B | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| EBITDA | (2.35 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 6.60 % | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (1.02 M) | ||||
| Total Asset | 2.16 M | ||||
| Retained Earnings | (41.89 M) | ||||
About Curative Biotechnology Performance
Assessing Curative Biotechnology's fundamental ratios provides investors with valuable insights into Curative Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Curative Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Curative Biotechnology, Inc. operates as a development-stage biomedical company. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida. Curative Biotechnology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Curative Biotechnology performance evaluation
Checking the ongoing alerts about Curative Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Curative Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Curative Biotechnology had very high historical volatility over the last 90 days | |
| Curative Biotechnology has some characteristics of a very speculative penny stock | |
| Curative Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Curative Biotechnology currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 132.32 K. Net Loss for the year was (3.56 M) with profit before overhead, payroll, taxes, and interest of 100.21 K. | |
| Curative Biotechnology currently holds about 126.85 K in cash with (1.02 M) of positive cash flow from operations. | |
| Curative Biotechnology has a poor financial position based on the latest SEC disclosures |
- Analyzing Curative Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Curative Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Curative Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Curative Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Curative Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Curative Biotechnology's stock. These opinions can provide insight into Curative Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.